{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:47:11Z","timestamp":1788670031860,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508106"],"award-info":[{"award-number":["2023YFC2508106"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["24YF2738100"],"award-info":[{"award-number":["24YF2738100"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["2025GDZKZD06"],"award-info":[{"award-number":["2025GDZKZD06"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273510"],"award-info":[{"award-number":["82273510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430101"],"award-info":[{"award-number":["82430101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102583","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T21:03:51Z","timestamp":1748639031000},"page":"102583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeted immunotherapy of psoriasis: focusing on Janus kinase\/signal transducers and activators of transcription signaling pathway"],"prefix":"10.1016","volume":"95","author":[{"given":"Zeyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-7881","authenticated-orcid":false,"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102583_bib1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41590-018-0256-2","article-title":"The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2025.102583_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.5270","article-title":"Psoriasis","volume":"327","author":"Walter","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.coi.2025.102583_bib3","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64 2","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102583_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/smi.3498","article-title":"Association between FABP7-5-HT pattern and anxiety or depression in patients with psoriasis: a cross-sectional study","volume":"40","author":"Huang","year":"2024","journal-title":"Stress Health"},{"key":"10.1016\/j.coi.2025.102583_sbref5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jad.2023.10.018","article-title":"Lesion area reduction and the amelioration of anxiety and depression states in psoriasis patients: a prospective clinical study","volume":"344","author":"Yu","year":"2024","journal-title":"J Affect Disord"},{"key":"10.1016\/j.coi.2025.102583_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102583_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.857164","article-title":"The role of IL-17-mediated inflammatory processes in the pathogenesis of intervertebral disc degeneration and herniation: a comprehensive review","volume":"10","author":"Suyama","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.coi.2025.102583_bib8","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.coi.2025.102583_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2013.10.009","article-title":"Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice","volume":"39","author":"Kumari","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102583_bib10","first-page":"2733","article-title":"Psoriasis 1' reduces psoriasis\u2011like skin inflammation by inhibiting the VDR\u2011mediated nuclear NF\u2011\u03baB and STAT signaling pathways","volume":"18","author":"Sun","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.coi.2025.102583_bib11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/jid.2011.222","article-title":"IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms","volume":"131","author":"Shi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib12","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.7150\/ijbs.83141","article-title":"Keratin 17 covalently binds to alpha-enolase and exacerbates proliferation of keratinocytes in psoriasis","volume":"19","author":"Luo","year":"2023","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.coi.2025.102583_bib13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/exd.13750","article-title":"RIP4 upregulates CCL20 expression through STAT3 signalling in cultured keratinocytes","volume":"27","author":"Bae","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102583_bib15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102583_sbref16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","article-title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","volume":"75","author":"Feldman","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib22","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102583_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102583_bib24","first-page":"275","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheuma Ther"},{"key":"10.1016\/j.coi.2025.102583_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheuma Ther"},{"key":"10.1016\/j.coi.2025.102583_bib26","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102583_bib27","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102583_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.coi.2025.102583_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib33","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/pharmaceutics16101287","article-title":"Lipid-based formulation of baricitinib for the topical treatment of psoriasis","volume":"16","author":"Mohammadi-Meyabadi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.coi.2025.102583_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102583_sbref38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib39","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib43","unstructured":"Dahlman T. : Alumis Presents Positive Data From Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting 2024-03-09 [cited 2025 01\u201307]. Available from: \u3008https:\/\/www.biospace.com\/alumis-presents-positive-data-from-phase-2-clinical-trial-of-esk-001-an-oral-allosteric-tyk2-inhibitor-for-the-treatment-of-plaque-psoriasis-at-aad-annual-meeting\u3009."},{"key":"10.1016\/j.coi.2025.102583_bib44","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3390\/jcm13113091","article-title":"Therapeutic potential of targeting the JAK\/STAT pathway in psoriasis: focus on TYK2 inhibition","volume":"13","author":"Dragotto","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2025.102583_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100116","article-title":"The relapse of psoriasis: mechanisms and mysteries","volume":"2","author":"Tian","year":"2022","journal-title":"JID Innov"},{"key":"10.1016\/j.coi.2025.102583_sbref45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: from remission to recurrence","volume":"154","author":"Francis","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102583_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109183","article-title":"Advancements in the characterization of tissue resident memory T cells in skin disease","volume":"245","author":"Li","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102583_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102424","article-title":"JAK\/STAT signaling controls the fate of CD8(+)CD103(+) tissue-resident memory T cell in lupus nephritis","volume":"109","author":"Zhou","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102583_bib49","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jid.2020.04.027","article-title":"Jak inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells","volume":"141","author":"Azzolino","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102583_bib50","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.stem.2021.07.001","article-title":"Establishment, maintenance, and recall of inflammatory memory","volume":"28","author":"Larsen","year":"2021","journal-title":"Cell Stem Cell"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:02:25Z","timestamp":1779084145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"alternative-id":["S0952791525000597"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102583","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted immunotherapy of psoriasis: focusing on Janus kinase\/signal transducers and activators of transcription signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102583"}}